Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study.

Authors:
Dr Sanjay Chatterjee, MD
Dr Sanjay Chatterjee, MD
Apollo Gleneagles Hospital
Consultant Diabetologist
Diabetology
Kolkata, West Bengal | India

J Diabetes 2014 May 27;6(3):237-42. Epub 2013 Aug 27.

Apollo Gleneagles Hospital, Kolkata, India.

Background: To analyze the glycemic response of Indian patients with type2 diabetes mellitus (T2DM) to combination therapy with vildagliptin and metformin and compare our data with those of clinical trials.

Methods: In a retrospective study of the hospital database, the glycemic control of 280 patients with T2DM who were either on a once- or twice-daily regimen of combination therapy with vildagliptin 50 mg and metformin 500 mg was analyzed.

Results: The mean duration of follow-up of the patients was 16.8 months. There was a reduction in fasting plasma glucose (FPG) of 1.52 ± 0.79 and 1.88 ± 0.87 mmol/L in the once- and twice-daily groups, respectively (both P < 0.0001) from baseline to last visit. The reduction in postprandial plasma glucose (PPPG) in the once- and twice-daily groups was 3.98 ± 1.72 and 4.33 ± 1.88 mmol/L, respectively (both P < 0.0001), whereas the reduction in HbA1c was 1.41 ± 1.39% and 1.90 ± 1.49%, respectively (both P < 0.0001). The differences in the reductions achieved in FPG and HbA1c with the two dosing regimens were significant.

Conclusion: Although the present retrospective study shows a robust response to the combination of vildagliptin and metformin in Indian patients, more multicenter studies from India with a greater number patients are necessary to confirm this finding.

Download full-text PDF

Source
http://dx.doi.org/10.1111/1753-0407.12078DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
May 2014
86 Reads
3 Citations

Publication Analysis

Top Keywords

combination therapy
12
indian patients
8
once- twice-daily
8
vildagliptin metformin
8
therapy vildagliptin
8
vildagliptin 50 mg
4
280 patients
4
patients t2dm
4
t2dm once-
4
control 280
4
regimen combination
4
twice-daily regimen
4
database glycemic
4
clinical trialsmethods
4
data clinical
4
compare data
4
trialsmethods retrospective
4
retrospective study
4
50 mg metformin
4
hospital database
4

References

(Supplied by CrossRef)
Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Inzucchi et al.
Diabetes Care. 2012
Gastrintestinal peptides: Role in pathophysiology and disease
Creutzfeldt et al.
Scand J Gastroenterol Suppl. 1982
The glucagon-like peptides
Kieffer et al.
Endocr Rev. 1999

Similar Publications